gmp
gmp

Find Novel Neurology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tricaprylin

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            Tricaprilin, is an investigational oral drug version of a medium chain triglyceride, which has been designed to induce ketosis and thereby improve mitochondrial metabolism.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Golimumab

            Therapeutic Area: Neurology Product Name: ION373

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2020

            Details:

            ION373 is an Ionis-owned investigational antisense medicine designed to stop the mutated gene from producing excess GFAP. Earlier this year, the European Medicines Agency (EMA) granted orphan drug designation to ION373.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): M102

            Therapeutic Area: Neurology Product Name: M102

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: FightMND

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Funding September 29, 2020

            Details:

            The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PBFT02

            Therapeutic Area: Neurology Product Name: PBFT02

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            In the study, a single administration of an optimized adeno-associated virus containing the GRN gene resulted in elevated levels of progranulin in the brain and cerebral spinal fluid, normalized lysosomal enzyme expression and corrected microgliosis in a mouse models.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Levodopa

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 16, 2020

            Details:

            LiberaTx, an NTU-incubated start-up is now commercialising new slow-release pill that delivers L-dopa over a period of 24 hours, which could help to alleviate symptoms related to Parkinson’s disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RNA editing therapies

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Wu Capital

            Deal Size: $91.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 10, 2020

            Details:

            This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. Korro’s OPERA platform, harnesses the body’s natural base editing system, specifically ADAR to make targeted edits to a single RNA base.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 4-Chlorokynurenine,Probenecid

            Therapeutic Area: Neurology Product Name: AV-101

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 03, 2020

            Details:

            The results of this new study complement previous preclinical data demonstrating the combination's potential to substantially increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, thereby reducing, rather than blocking, NMDA receptor signaling.

            Universities of Liverpool

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ebselen

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            The team have developed a number of ebselen-based compounds with improvements in SOD1 stabilisation and in vitro therapeutic effects with significantly better potency than edaravone.

            University of Kentucky

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AL002

            Therapeutic Area: Neurology Product Name: AL002

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            5XFAD mice in the intracranial administration study were assigned to one of two injection groups: AL002a, a Trem2-agonizing antibody, or MOPC, an isotype-matched control antibody.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KLS-13019

            Therapeutic Area: Neurology Product Name: KLS-13019

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 25, 2020

            Details:

            With the PCT Patent, along with Kannalife’s novel lead drug candidate, KLS-13019, and its other novel therapeutic agents like Atopidine™, Kannalife now has near global coverage in the top pharmaceutical markets in the world.

            PharmaCompass